SLC26A4 and hearing loss disorder: Our study suggests that gene therapy for hearing loss caused by SLC26A4 mutations in human patients is feasible, however, ethical concerns should prevent a direct translation, since local gene delivery amounts to an invasive procedure for a non-lethal disease.